Presentation Type: Speech
Heart failure (HF) is a common, lethal, disabling, and expensive disorder. Its prevalence in industrialized nations has reached epidemic proportions and continues to rise. Despite significant therapeutic advances, the prognosis of patients with heart failure (HF) remains poor, and current therapeutic approaches are palliative in the sense that they do not address the underlying problem of the loss of cardiac tissue. Cell-based therapy is an emerging treatment modality for cardiovascular disease specially heart failure. However, many clinical trials have been conducted, the optimal cell source and delivery technique yet remain to be defined. According to the last meta-analyses studies, administration of any dose of cells by any delivery route in comparison with no intervention or placebo significantly reduced the risk of mortality and rehospitalization. There were the significant improvement in left ventricular ejection fraction and quality of life. The treatment was also associated with a reduction of brain natriuretic peptide levels and no increase in the incidence of arrhythmias. In conclusion previous studies show evidence that cell based therapy may be beneficial for patients having ischemic cardiovascular disease but further evidence is required.